Shaji Kumar, MD, consultant in the Division of Hematology and professor of medicine at Mayo Clinic Cancer Center in Rochester, Minnesota, highlighted treatments of interest in the pipeline for multiple myeloma and how the treatment paradigm may change in the coming years.

Watch part 1 of the interview with Dr. Kumar where he discusses the first approved anti-BCMA therapy.

Watch part 2 of the interview with Dr. Kumar, where he discusses results of the ENDURANCE trial.